Certara (CERT) is back in focus after its physiologically based pharmacokinetic modeling underpinned the U.S. FDA review of asciminib, with simulations accepted in place of several clinical pharmacology studies for the cancer drug’s new drug application.

Despite the FDA validation of its PBPK modeling and a recent earnings update, Certara’s share price return has been weak, with a 30 day share price return of 7.23% decline and a 1 year total shareholder return of 39.81% decline. This suggests sentiment has been fading even as its technology gains regulatory relevance.

If this FDA backed use case has you thinking about where else modeling and data heavy platforms could matter, it might be a good time to scan 32 healthcare AI stocks as potential ideas to research next.

With the share price under pressure, annual revenue growth of 4.51% and a small net loss of US$1.6 million, the key question is whether Certara is now mispriced value or if the market already sees all the potential future growth.

Most Popular Narrative: 42.9% Undervalued

Certara’s most followed valuation narrative puts fair value at $12.38 per share versus the last close at $7.06, framing a sizeable gap investors will want to understand.

The upcoming commercial launch of Certara's next-generation, AI-enabled MIDD platform and CertaraIQ QSP software leverages advanced analytics and machine learning, providing differentiated capabilities that democratize access and increase the potential customer base, which should translate to higher recurring revenue and margin expansion through cloud-based SaaS models.

Curious what kind of growth and margin profile could justify that valuation gap, especially with a modest revenue forecast and a low single digit profit margin assumption shaping this fair value story?

Result: Fair Value of $12.38 (UNDERVALUED)

However, there is still a real chance that slower pharma adoption, rising costs or weaker bookings, especially from larger customers, could keep pressure on Certara’s earnings path.

Another Angle On Valuation

Here is the catch. While the fair value narrative and our DCF model both point to Certara looking undervalued, the P/S ratio tells a different story. At 2.7x, the shares trade richer than the US Healthcare Services average of 2.2x and above a fair ratio of 1.8x. This suggests the market could still mark the multiple lower. So is this a genuine pricing gap or just a model that is too optimistic?

Next Steps

If this mix of weak recent returns and upbeat valuation stories feels a bit conflicted, consider acting promptly and assess the potential upside yourself with 3 key rewards.

Looking for more investment ideas?

If Certara has caught your attention, do not stop here. Use this momentum to widen your watchlist with a few focused sets of opportunities.

• Target potential mispricings by scanning our collection of 50 high quality undervalued stocks that combine solid fundamentals with prices that may not fully reflect their underlying business strength.
• Prioritise resilience by checking out 63 resilient stocks with low risk scores, where companies show lower risk scores that could suit investors who prefer a steadier ride.
• Hunt for underfollowed opportunities through our screener containing 24 high quality undiscovered gems, a list built to surface quality businesses that may not yet be widely on the radar.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.